نتایج جستجو برای: beta interferon

تعداد نتایج: 247907  

Journal: :Journal of virology 1989
J S Twu R H Schloemer

The manner by which the trans-acting factor encoded by the 1,828-base-pair (bp) BamHI DNA fragment of hepatitis B virus (HBV) suppresses the production of human beta interferon was determined. Steady-state levels of RNA specific for human beta interferon were decreased in cells that contained the 1,828-bp BamHI DNA fragment of HBV. The reduced accumulation of interferon-specific RNA was due to ...

Journal: :Cancer research 1989
D Goldstein S M Bushmeyer P L Witt V C Jordan E C Borden

The combined effects of tamoxifen, a competitive inhibitor of estrogen, and type I or II interferons on the proliferation of several human breast cancer cell lines in vitro were examined. Additive antiproliferative effects were observed with interferons and tamoxifen, in two estrogen receptor positive cell lines, MCF-7 and T-47D. In MCF-7 cells neither beta ser interferon, gamma interferon, nor...

Journal: :Anais brasileiros de dermatologia 2011
Dário Júnior de Freitas Rosa Fernanda de Abreu Toledo Matias Sâmya Diégues Cedrim Ronaldo Figueiredo Machado Alessandra Almeida Montenegro de Sá Vânia Carolina Piccinini Silva

Multiple sclerosis is an inflammatory demyelinating disease of presumed autoimmune origin that affects the central nervous system. The main form of therapy is based on the use of immunomodulators such as interferon beta, which are usually well tolerated. Skin manifestations resulting from treatment with interferon beta-1b consist principally of reactions at the site of subcutaneous application ...

Journal: :Neurology 2005
Emmanuelle Waubant A Dessa Sadovnick

Many women with multiple sclerosis (MS) ask about the risks of pregnancy before starting (or while on) disease-modifying therapies (DMTs). At least twothirds of patients with MS are women, and the majority are in their childbearing years at the time of clinical onset and diagnosis. DMTs taken during pregnancy could have direct or indirect toxicity (through immunomodulating properties) on pregna...

2013
Julien Mahe Aurélie Meurette Anne Moreau Caroline Vercel Pascale Jolliet

Interferon beta-1a is available as an immunomodulating agent for relapsing forms of multiple sclerosis. Common side effects include flu-like symptoms, asthenia, anorexia, and administration site reaction. Kidney disorders are rarely reported. In this study we describe the case of a woman who has been undergoing treatment with interferon beta-1a for multiple sclerosis for 5 years. She developed ...

Journal: :Lancet 2012
Alasdair J Coles Cary L Twyman Douglas L Arnold Jeffrey A Cohen Christian Confavreux Edward J Fox Hans-Peter Hartung Eva Havrdova Krzysztof W Selmaj Howard L Weiner Tamara Miller Elizabeth Fisher Rupert Sandbrink Stephen L Lake David H Margolin Pedro Oyuela Michael A Panzara D Alastair S Compston

BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment. METHODS In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled ad...

Journal: :Journal of virology 2000
R Deonarain A Alcamí M Alexiou M J Dallman D R Gewert A C Porter

We have generated mice lacking the gene for beta interferon and report that they are highly susceptible to vaccinia virus infection. Furthermore, in cultured embryo fibroblasts, viral induction of alpha interferon and of 2-5A synthetase genes is impaired. We also show that beta interferon does not prime its own expression.

Journal: :The Lancet. Neurology 2011
Scott S Zamvil Lawrence Steinman

672 www.thelancet.com/neurology Vol 10 August 2011 Since the fi nding that cholesterol-lowering statins could induce T-cell-mediated immune modulation and reverse paralysis in mice with experimental autoimmune encephalomyelitis (EAE), there has been substantial interest in whether this class of drugs is benefi cial in multiple sclerosis. One question that has not been answered is whether a stat...

Journal: :Archives of neurology 1999
D C Mohr W Likosky P Dwyer J Van Der Wende A C Boudewyn D E Goodkin

OBJECTIVE To examine the hypothesis that increases in depression after initiation of treatment with interferon beta-1a for multiple sclerosis can be explained as representing a return to pretreatment levels of depression. DESIGN Level of depression in patients with multiple sclerosis was assessed at 3 time points: 2 weeks before initiation of interferon beta-la treatment, at initiation of tre...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید